Most recently, Icenticaftor, another oral investigational compound that potentiates CFTR in-vitro [10], was evaluated for 12 weeks in Phase IIb clinical trials in > 900 patients with COPD. This evidence concerns the gene CFTR and chronic obstructive pulmonary disease.